drugset / Trial / NCT02274181

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

NCT02274181

Phase 1 Completed 6 enrolled Repros Therapeutics Inc. Celerion · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to \[(\~\]) 500 nanocurie \[nCi\]) dose of \[14C\]Androxal in healthy adult male subjects.

Timeline

Start
2014-12
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Androxal Unknown 25 mg Oral

Indications